Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0002199,
umls-concept:C0019196,
umls-concept:C0030705,
umls-concept:C0150312,
umls-concept:C0166049,
umls-concept:C0205191,
umls-concept:C0439849,
umls-concept:C0445223,
umls-concept:C0871261,
umls-concept:C1552599,
umls-concept:C1704632,
umls-concept:C1704787,
umls-concept:C1706817,
umls-concept:C2911692
|
pubmed:issue |
1
|
pubmed:dateCreated |
1990-10-18
|
pubmed:abstractText |
The purpose of this study was to determine whether the response of serum alanine aminotransferase (ALT) to recombinant alpha-interferon was related to the presence or absence of antibodies to hepatitis C virus (anti-HCV) in patients with chronic non-A,non-B hepatitis. A group of 65 patients with chronic non-A, non-B hepatitis was studied. The source of contamination was blood transfusion or administration of blood products in 32, intravenous drug addiction in 14 and unknown in 19. The patients received 1, 3 or 5 MU of recombinant alpha-interferon, three times a week, for 6 months. A complete response was defined as normal ALT by the end of recombinant alpha-interferon treatment. Sera collected before treatment were tested for anti-HCV with an enzyme immunoassay. The overall percentage of anti-HCV positive patients in the study group was 75%. There was no difference between the anti-HCV positive and the anti-HCV negative patients before the treatment with respect to age, sex ratio, source of contamination, serum albumin, prothrombin, bilirubin, ALT or prevalence of cirrhosis. In the anti-HCV positive and the anti-HCV negative groups, there was no difference in the proportion of patients receiving the 1, 3 or 5 MU dosage. The percentage of patients with complete response was not different in anti-HCV positive patients (48%) and in anti-HCV negative patients (50%). There was also no difference in the kinetics of the decrease of mean serum ALT levels between the two groups.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Alanine Transaminase,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Hepatitis Antibodies,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon Type I,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0168-8278
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
11
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
77-9
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:2118928-Adult,
pubmed-meshheading:2118928-Alanine Transaminase,
pubmed-meshheading:2118928-Antibodies, Viral,
pubmed-meshheading:2118928-Female,
pubmed-meshheading:2118928-Hepatitis, Viral, Human,
pubmed-meshheading:2118928-Hepatitis Antibodies,
pubmed-meshheading:2118928-Hepatitis C,
pubmed-meshheading:2118928-Hepatitis Viruses,
pubmed-meshheading:2118928-Humans,
pubmed-meshheading:2118928-Interferon Type I,
pubmed-meshheading:2118928-Male,
pubmed-meshheading:2118928-Middle Aged,
pubmed-meshheading:2118928-Recombinant Proteins
|
pubmed:year |
1990
|
pubmed:articleTitle |
Is the response to recombinant alpha interferon related to the presence of antibodies to hepatitis C virus in patients with chronic non-A, non-B hepatitis?
|
pubmed:affiliation |
Service d'Hépatologie, Hôpital Beaujon, Clichy, France.
|
pubmed:publicationType |
Journal Article
|